Journal of Oral and Maxillofacial Surgery
Volume 66, Issue 2 , Pages 223-230 , February 2008

Outcomes of Placing Dental Implants in Patients Taking Oral Bisphosphonates: A Review of 115 Cases

  • Bao-Thy Grant, DDS

      Affiliations

    • Chief Resident, Department of Oral and Maxillofacial Surgery, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.
    • ,
  • Christopher Amenedo, DDS

      Affiliations

    • Attending, Department of Oral and Maxillofacial Surgery, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.
    • ,
  • Katherine Freeman, DrPH

      Affiliations

    • Professor, Department of Epidemiology and Population Health, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.
    • ,
  • Richard A. Kraut, DDS

      Affiliations

    • Chairman of Department of Dentistry, Director of Oral and Maxillofacial Surgery, and Professor, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.
    • Corresponding Author InformationAddress correspondence and reprint requests to Dr Kraut: Montefiore Medical Center, Dentistry/Oral and Maxillofacial Surgery, 111 East 210th Street, Bronx, NY 10467-2460

References 

  1. Ruggerio SI, Mekrotra B, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates (A review of 63 cases). J Oral Maxillofac Surg. 2004;62:527
  2. Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol. 2000;18:1378
  3. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20:3719
  4. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol. 2003;21:4253
  5. Marx RE. Pamidromate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg. 2003;61:1115
  6. Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947
  7. Marx RE. Oral and Intravenous Bisphosphonate-Induced Osteonecrosis of the Jaws. Hanover Park, IL: Quintessence; 2007;
  8. American Dental Association Council on Scientific Affairs: Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations. J Am Dent Assoc. 2006;137:1144
  9. US Department of Health and Human Services. Bone health and osteoporosis: A report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; 2004;
  10. American Dental Association Council on Scientific Affairs: Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations. J Am Dent Assoc. 2006;137:1144
  11. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369
  12. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaws and bisphosphonates. N Engl J Med. 2005;353:99
  13. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol. 2005;23:8580
  14. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006;91:968
  15. Zavras AI, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data; Is it osteonecrosis?. J Oral Maxillofac Surg. 2006;64:917
  16. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/psteopetrosis) of the jaws (Risk factors, recognition, prevention, and treatment). J Oral Maxillofac Surg. 2005;63:1567
  17. Ruggiero SL, Mehrotra B. Ten years of alendronate treatment for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189
  18. Schwartz HC. Osteonecrosis and bisphosphonates: Correlation versus causation. J Oral Maxillofac Surg. 2004;62:763
  19. Albrektsson T, Zarb G, Worthington P, et al. : The long-term efficacy of currently used dental implants: A review and proposed criteria of success. Int J Oral Maxillofac Implants. 1986;1:11
  20. Stark WJ, Epker BN. Failure of osteointegrated dental implants after diphosphonate therapy for osteoporosis: A case report. Int J Oral Maxillofac Implants. 1995;10:74
  21. Chapurlat R, Meunier PJ. Bisphosphonates and bone remodeling: Effectiveness in Paget’s disease, fibrous dysplasia, and osteoporosis [in French]. Rev Chir Orthop Reparatrice Appar Mot. 1998;84:743
  22. Jeffcoat MK. Safety of oral bisphosphonates: Controlled studies on alveolar bone. Int J Oral Maxillofac Implants. 2006;21:349
  23. Rosen HN, Moses AC, Garber J, et al. Serum CTX (A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy). Calcif Tissue Int. 2000;66:100

PII: S0278-2391(07)01876-9

doi: 10.1016/j.joms.2007.09.019

Journal of Oral and Maxillofacial Surgery
Volume 66, Issue 2 , Pages 223-230 , February 2008

Article Tools

* Image Usage & Resolution